Adjuvant bisphosphonates in patients with breast cancer: does the potency matter? - Wikidata - awgldk - TriplyDB

Adjuvant bisphosphonates in patients with breast cancer: does the potency matter?

Adjuvant bisphosphonates in patients with breast cancer: does the potency matter?

http://www.wikidata.org/entity/Q26781435

about

Bisphosphonate use and the risk of breast cancer: a meta-analysis of observational studies.

P2860

Q48148231-42419C9A-F2D5-490D-B44C-5A573D4EE0E3

P2860

Adjuvant bisphosphonates in patients with breast cancer: does the potency matter?

http://www.wikidata.org/entity/Q26781435

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Adjuvant bisphosphonates in patients with breast cancer: does the potency matter?

@ast

Adjuvant bisphosphonates in patients with breast cancer: does the potency matter?

@en

Adjuvant bisphosphonates in patients with breast cancer: does the potency matter?

@nl

type

label

Adjuvant bisphosphonates in patients with breast cancer: does the potency matter?

@ast

Adjuvant bisphosphonates in patients with breast cancer: does the potency matter?

@en

Adjuvant bisphosphonates in patients with breast cancer: does the potency matter?

@nl

prefLabel

Adjuvant bisphosphonates in patients with breast cancer: does the potency matter?

@ast

Adjuvant bisphosphonates in patients with breast cancer: does the potency matter?

@en

Adjuvant bisphosphonates in patients with breast cancer: does the potency matter?

@nl

P1433

Q26781435-B8E646ED-D9AA-4BFD-A93C-8C58F4F6220C

P1476

Q26781435-D6746F8B-72CF-4AD7-AD12-F8FF61B2E0E5

P2093

Q26781435-144F4699-F846-406E-A8F5-AFFE1DB75B6A

Q26781435-4C996289-B21B-4EC3-A116-A768BCE16636

Q26781435-662DBB28-5355-4E65-97F2-E0E86EDF60C8

Q26781435-991917C9-E475-43E8-8BB6-D27D420FFD1D

Q26781435-C874A57C-8F55-4050-B57F-E2BBC88278D1

P2860

Q26781435-0948901B-CECF-4C20-82C3-0B844A43D096

Q26781435-3F3E2AB2-24E6-4CB2-89EA-213D568CC057

Q26781435-4BA20963-4824-4DAF-8328-9E5833F0AB15

Q26781435-55B1EE2F-9ABB-4DF6-90D8-4EDA82BF31FB

Q26781435-55FD346E-D798-450A-8834-FA34F51B3C08

Q26781435-5E3EA158-0905-4B5C-9C93-5B53B8702ADA

Q26781435-71294F34-B641-4032-852C-13BCC5226493

Q26781435-87AB3F10-D751-497C-B199-A983BF60FF43

Q26781435-8C41825C-4D62-4FE8-8166-61C9E61AD80D

Q26781435-A6DF71C8-77ED-4987-80BC-368D83E487FD

P304

Q26781435-9E894FB0-4EFE-4AA5-BFF1-011F5B788F74

P31

Q26781435-1E3701D2-D21E-4BA9-A15A-A0CF30221717

Q26781435-37e01110-2329-4222-8989-46039dda70e0

Q26781435-af186c1a-685e-48ae-a0aa-f1c40cf77a02

P356

Q26781435-BB4E99E7-EBFF-486B-BE40-DF4034C9297C

P407

Q26781435-4776689B-5CE4-45C4-8C25-8D3A4A10CC07

P433

Q26781435-03F9084B-A1B8-4354-87C3-12F8AA3A949A

P478

Q26781435-EF073391-4A2A-4635-9920-BEDBE96B8CCB

P50

Q26781435-36AA7A76-9B5D-495F-A0EE-824E52745D27

Q26781435-D7ECAFCC-D179-4F80-A20C-3124746B60C5

P577

Q26781435-78F2F8C0-C198-4A12-B369-1803E596714B

P698

Q26781435-D6EEF6FF-5A77-434C-80E5-77520BB2E683

P356

P1433

Future Oncology

P1476

Adjuvant bisphosphonates in patients with breast cancer: does the potency matter?

@en

P2093

Alfredo Berruti

http://www.w3.org/2001/XMLSchema#string

Edda Lucia Simoncini

http://www.w3.org/2001/XMLSchema#string

Fausto Petrelli

http://www.w3.org/2001/XMLSchema#string

Rebecca Pedersini

http://www.w3.org/2001/XMLSchema#string

Sandro Barni

http://www.w3.org/2001/XMLSchema#string

P2860

Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

Impact of parathyroid hormone on bone marrow-derived stem cell mobilization and migration

Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.

Role of N-cadherin in bone formation.

Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer

Vitamin d deficiency in postmenopausal breast cancer survivors.

The multifaceted actions of PTHrP in skeletal metastasis

Cancer to bone: a fatal attraction.

P304

2853-2856

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.15.210

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Philippe Clézardin

P577

2015-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26403833

http://www.w3.org/2001/XMLSchema#string